Year 2017 / Volume 109 / Number 9
Letter to the Editor
Fecal transplantation as a treatment for Clostridium difficile infection in patients with ulcerative colitis

670

DOI: 10.17235/reed.2017.4941/2017

Marta Izquierdo Romero, Pilar Varela Trastoy, Alejo Mancebo Mata,

Abstract
Clostridium difficile (CD) infection is currently the most frequent etiology of nosocomial diarrhea. Besides, its incidence is progressively increasing in ambulatory patients. Inflammatory bowel disease (IBD) is a risk factor of CD infection itself, but also due to the regular immunosuppressive treatment used in these patients. At the present time, fecal transplantation (FT) is a safe and cost-effective alternative if the previous antibiotic treatments have failed. Similar outcomes between patients with IBD and general population have been reported. We present a case of a patient with ulcerative colitis and recurrent CD infection successfully treated with FT.
Share Button
New comment
Comments
No comments for this article
References
Fischer M, Kao D, Kelly C, Kuchipudi A, Jafri S, Blumenkehl M, et al. Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016; 22: 2402-2409.
DOI: 10.1097/MIB.0000000000000908
Di Bella S, Gouliouris T and Petrosillo N. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patients. J Infect Chemother. 2015; 21: 230-237.
DOI: 10.1016/j.jiac.2015.01.011
Leffler D and Lamont J. Clostridium difficile Infection. N Engl J Med. 2015; 372: 1539-1548.
DOI: 10.1056/NEJMra1403772
Ramos Martínez A, Ortiz Balbuena J, Curto García I, Asensio Vegas A, Martínez Ruiz R, Múñez Rubio E, et al. Factores de riesgo de diarrea por Clostridium difficile en pacientes con enfermedad inflamatoria intestinal. Rev Esp Enferm Dig. 2015; 107(1): 4-9.
Ponte A, Pinho R, Mota M, Silva J, Vieira N, Oliveira R, et al. Initial experience with fecal microbiota transplantation in Clostridium difficile infection – transplant protocol and preliminary results. Rev Esp Enferm Dig. 2015; 107(7): 402-407.
DOI: 10.17235/reed.2015.3767/2015
Related articles

Original

Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease

DOI: 10.17235/reed.2024.10305/2024

Letter

An Epstein-Barr virus-positive mucocutaneous ulcer in a patient with ulcerative colitis: a recently described entity to take into account

DOI: 10.17235/reed.2024.10168/2023

Letter

Long-term remission achieved in a rare case of pyoderma gangrenosum and ulcerative colitis with surgery and postoperative infliximab

DOI: 10.17235/reed.2024.10144/2023

Letter

Intestinal stenosis developed after a complete response to chemotherapy in a patient with Crohn’s disease and lymphoma of the jejunum

DOI: 10.17235/reed.2023.10004/2023

Letter

Ulcerative colitis induced by obinutuzumab in a patient treated for a follicular lymphoma

DOI: 10.17235/reed.2023.10009/2023

Letter

Effectiveness of 4 L, 2 L, and 1 L polyethylene glycol (PEG) bowel preparation for colonoscopy in patients with ulcerative colitis: a retrospective study

DOI: 10.17235/reed.2023.9979/2023

Letter

Vancomycin in the treatment of inflammatory bowel disease: there is a role beyond Clostridioides difficile infection

DOI: 10.17235/reed.2023.9942/2023

Original

Psychological disorders and coping strategies in patients with inflammatory bowel disease. Their impact on health-related quality of life

DOI: 10.17235/reed.2023.9935/2023

Letter

Is cervical dysplasia a major concern in females with inflammatory bowel disease? A Spanish retrospective study

DOI: 10.17235/reed.2023.9890/2023

Letter

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Original

Sarcopenia and treatment failure in inflammatory bowel disease: a systematic review and meta-analysis

DOI: 10.17235/reed.2023.9808/2023

Original

Ulcerative colitis overall disease severity index predicts colectomy: a prospective cohort study

DOI: 10.17235/reed.2023.9754/2023

Letter

Infliximab-induced psoriasis in an ulcerative colitis patient successfully treated with guselkumab

DOI: 10.17235/reed.2023.9745/2023

Original

Development and validation of a nomogram to predict non-response to 5-aminosalicylic acid in patients with ulcerative colitis

DOI: 10.17235/reed.2023.9703/2023

Letter

Extensive involvement of indolent T-cell lymphoma in a patient with ulcerative colitis

DOI: 10.17235/reed.2023.9623/2023

Letter

Iatrogenic rectal perforation due to application of topical treatment in a patient with ulcerative colitis: a rare complication

DOI: 10.17235/reed.2023.9599/2023

Original

Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis

DOI: 10.17235/reed.2023.9537/2023

Original

Fecal immunochemical test for hemoglobin versus fecal calprotectin to monitor endoscopic activity in inflammatory bowel disease

DOI: 10.17235/reed.2023.9536/2023

Letter

Severe outbreak of ulcerative colitis and cerebral neoplasia. Difficult management in COVID time

DOI: 10.17235/reed.2023.9527/2023

Original

The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab

DOI: 10.17235/reed.2023.9491/2023

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Editorial

Relevance of patient-reported outcome measures (PROM) and patient-reported experience measures (PREM) to assess disease status and quality of care in patients with inflammatory bowel disease

DOI: 10.17235/reed.2023.9563/2022

Letter

Reply: SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents

DOI: 10.17235/reed.2023.9438/2022

Letter

Henoch-Schönlein purpura masquerading as Crohn’s disease flare

DOI: 10.17235/reed.2022.9414/2022

Letter

SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: correspondence

DOI: 10.17235/reed.2023.9347/2022

Letter

Prediagnosis of soft tissue infection that was finally diagnosed as pyoderma gangrenosum of ulcerative colitis

DOI: 10.17235/reed.2022.9332/2022

Letter

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Original

Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis

DOI: 10.17235/reed.2022.9264/2022

Letter

A rare case of ulcerative colitis following Bacillus Calmette-Guérin therapy

DOI: 10.17235/reed.2022.9191/2022

Letter

Ulcerative colitis complicated by autoimmune hepatitis-primary biliary cholangitis-primary sclerosing cholangitis overlap syndrome

DOI: 10.17235/reed.2022.9183/2022

Letter

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Letter

Crohn’s disease induced by ocrelizumab in a patient with multiple sclerosis

DOI: 10.17235/reed.2022.9152/2022

Letter

Pyoderma gangrenosum in ulcerative colitis - An exuberant and painful complication

DOI: 10.17235/reed.2022.9120/2022

Original

Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study

DOI: 10.17235/reed.2022.9101/2022

Letter

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Review

“Out of the box” new therapeutic strategies for Crohn´s disease: moving beyond biologics

DOI: 10.17235/reed.2022.9010/2022

Letter

The neutrophil-lymphocyte ratio as a predictor of steroid response in patients with severe ulcerative colitis: a retrospective cohort study

DOI: 10.17235/reed.2022.9006/2022

Letter

Dual biologic therapy for severe ulcerative colitis, concomitant extraintestinal manifestations and an orbital osteoma: a successful treatment

DOI: 10.17235/reed.2022.8964/2022

Letter

A rare case of an intestinal ulcer: AIDS and amebic colitis in a homosexual man with ulcerative colitis

DOI: 10.17235/reed.2022.8903/2022

Review

Efficacy and safety of fecal microbiota transplant for recurrent Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis

DOI: 10.17235/reed.2022.8814/2022

Letter

One appendix too many: a severe IBD-U case in remission after appendectomy

DOI: 10.17235/reed.2022.8809/2022

Original

Impact of proactive therapeutic drug monitoring of infliximab during the induction phase in IBD patients. A Bayesian approach

DOI: 10.17235/reed.2022.8781/2022

Letter

Combined aortic mural thrombi and limb ischemia in inflammatory bowel disease – A rare vascular manifestation

DOI: 10.17235/reed.2022.8774/2022

Original

Health-related quality of life decline in clinically stable inflammatory bowel disease patients during the COVID-19 outbreak

DOI: 10.17235/reed.2022.8668/2022

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Mesalazine induced interstitial pneumonitis in the COVID era

DOI: 10.17235/reed.2022.8635/2021

Letter

Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center

DOI: 10.17235/reed.2021.8397/2021

Original

Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia

DOI: 10.17235/reed.2022.8380/2021

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Letter

Comparison of satisfaction degree of patients treated at the Inflammatory Bowel Disease Unit (IBDU) of Hospital Universitario 12 de Octubre between previous face-to-face care and telephone care during the COVID-19 pandemic

DOI: 10.17235/reed.2021.8185/2021

Review

Adherence improvement in patients with ulcerative colitis: a multidisciplinary consensus document

DOI: 10.17235/reed.2021.8130/2021

Original

Incidence of inflammatory bowel disease and phenotype at diagnosis in 2011: results of the Epi-IBD 2011 study in the Vigo area

DOI: 10.17235/reed.2021.8003/2021

Letter

ABP 501 (adalimumab-atto) in the treatment of inflammatory bowel disease: an example of evidence-based extrapolation

DOI: 10.17235/reed.2021.7921/2021

Original

Impact of Epstein-Barr virus infection on inflammatory bowel disease (IBD) clinical outcomes

DOI: 10.17235/reed.2021.7915/2021

Letter

Influence of the onset of the SARS-CoV-2 pandemic on the diagnosis and treatment of ulcerative colitis

DOI: 10.17235/reed.2021.7768/2020

Letter

The COVID-19 pandemic shows us in which way the care of patients with inflammatory bowel disease should move

DOI: 10.17235/reed.2021.7765/2020

Original

Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study

DOI: 10.17235/reed.2021.7683/2020

Original

Biosimilar infliximab CPT-13 for inflammatory bowel disease in a real clinical setting: pharmacokinetic outcomes, immunogenicity, and drug survival

DOI: 10.17235/reed.2021.7638/2020

Original

Thiopurine adherence: a high prevalence with low impact on UC outcomes

DOI: 10.17235/reed.2021.7630/2020

Letter

Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic

DOI: 10.17235/reed.2020.7562/2020

Original

Consequences and management of COVID-19 on the care activity of an Inflammatory Bowel Disease Unit

DOI: 10.17235/reed.2020.7543/2020

Letter

A case of severe diverticulosis in a patient with ulcerative colitis

DOI: 10.17235/reed.2020.7529/2020

Review

The use of contrast-enhanced ultrasound for chronic inflammatory bowel disease

DOI: 10.17235/reed.2020.7499/2020

Original

Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results

DOI: 10.17235/reed.2020.7472/2020

Letter

Intestinal obstruction secondary to Crohn-like disease in common variable immu-nodeficiency

DOI: 10.17235/reed.2020.7440/2020

Original

Prevalence of pyoderma gangrenosum and Sweet´s syndrome in inflammatory bowel disease at a tertiary healthcare center

DOI: 10.17235/reed.2020.7431/2020

Original

Evaluation of epicardial adipose tissue and carotid intima-media thickness as a marker of atherosclerosis in patients with inflammatory bowel disease

DOI: 10.17235/reed.2020.7394/2020

Editorial

Autoimmune hepatitis, primary sclerosing cholangitis, and inflammatory bowel disease. Sequential overlap syndrome: a twist to the mosaic of autoimmunity

DOI: 10.17235/reed.2020.7512/2020

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Original

Ustekinumab in Crohn's disease: real-world outcomes and predictors of response

DOI: 10.17235/reed.2020.7352/2020

Letter

Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn’s disease: the extrapolation concept

DOI: 10.17235/reed.2020.7253/2020

Original

Prevalence and factors associated with poor sleep quality in inflammatory bowel disease outpatients

DOI: 10.17235/reed.2020.7202/2020

Letter

Author´s answer to: “Effect of adacolumn® in ulcerative colitis with COVID-19”

DOI: 10.17235/reed.2020.7188/2020

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Review

COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic

DOI: 10.17235/reed.2020.7128/2020

Review

Vitamin D and inflammatory bowel disease: what do we know so far?

DOI: 10.17235/reed.2020.7061/2020

Original

Glasgow prognostic score is a predictive index for postoperative infectious complications after total proctocolectomy in ulcerative colitis patients

DOI: 10.17235/reed.2020.7047/2020

Letter

Sweet syndrome in severe ulcerative flare

DOI: 10.17235/reed.2020.6995/2020

Original

Autoimmune sequential overlap syndrome (autoimmune hepatitis/primary sclerosing cholangitis) and inflammatory bowel disease: three clinical cases

DOI: 10.17235/reed.2020.6938/2020

Letter

Gastrointestinal tuberculosis, the great simulator. From inflammatory disease to a tumor

DOI: 10.17235/reed.2020.6934/2020

Original

Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients

DOI: 10.17235/reed.2020.6857/2020

Original

Meta-analysis of protein intake on the effect of Crohn’s disease and ulcerative colitis

DOI: 10.17235/reed.2020.6851/2019

Original

Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn’s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain

DOI: 10.17235/reed.2020.6847/2019

Original

Index of the Mayo Endoscopy and Ulcerative Colitis Endoscopy Index of Severity: are they equally valid?

DOI: 10.17235/reed.2020.6832/2019

Letter

Vedolizumab-associated psoriasis: until where does gut selectivity go?

DOI: 10.17235/reed.2020.6817/2019

Letter

An acute episode of inflammatory bowel disease vs a rare manifestation of an Epstein-Barr virus-positive mucocutaneous ulcer. Case report

DOI: 10.17235/reed.2020.6737/2019

Editorial

Is celiac disease really associated with inflammatory bowel disease?

DOI: 10.17235/reed.2019.6779/2019

Original

Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn’s disease: an observational study

DOI: 10.17235/reed.2020.6693/2019

Original

Predictive factors of clinical response to treatment with anti-TNF agents in ulcerative colitis: what have we learned from our patients?

DOI: 10.17235/reed.2020.6688/2019

Original

Association between autoimmune pancreatitis and ulcerative colitis: a report of 12 patients

DOI: 10.17235/reed.2020.6677/2019

Letter

Intra-abdominal desmoid tumor and chronic inflammatory bowel disease. An uncommon scenario

DOI: 10.17235/reed.2020.6648/2019

Original

Quality of care through the eyes of the patient in a Spanish inflammatory bowel disease unit

DOI: 10.17235/reed.2020.6620/2019

Original

Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease

DOI: 10.17235/reed.2020.6618/2019

Original

Diet as an environmental trigger in inflammatory bowel disease: a retrospective comparative study in two European cohorts

DOI: 10.17235/reed.2020.6552/2019

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Review

Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis

DOI: 10.17235/reed.2019.6336/2019

Original

Status of transition care in inflammatory bowel disease in Spain. Different medical perspectives

DOI: 10.17235/reed.2019.6310/2019

Original

Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel disease

DOI: 10.17235/reed.2019.6298/2019

Original

Differences in the need for adalimumab dose optimization between Crohn’s disease and ulcerative colitis

DOI: 10.17235/reed.2019.6148/2018

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Original

The main determinants of disability in IBD and its relationship to optimism

DOI: 10.17235/reed.2019.6033/2018

Original

Treat to target in inflammatory bowel disease: a survey of treatment strategies amongst Portuguese doctors

DOI: 10.17235/reed.2019.6029/2018

Letter

A rare lymphoproliferative disorder associated with immunomodulating therapy in Crohn’s disease

DOI: 10.17235/reed.2019.5990/2018

Case Report

Leukocytoclastic vasculitis after vaccination in a patient with inflammatory bowel disease

DOI: 10.17235/reed.2019.5963/2018

Case Report

Serrated Lesions in patients with Inflammatory Bowel Disease.

DOI: 10.17235/reed.2019.5910/2018

Letter

The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?

DOI: 10.17235/reed.2019.5841/2018

Original

The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease

DOI: 10.17235/reed.2019.5797/2018

Original

Vitamin D deficiency in outpatients with inflammatory bowel disease: prevalence and association with clinical-biological activity

DOI: 10.17235/reed.2018.5714/2018

Original

Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease

DOI: 10.17235/reed.2019.5600/2018

Original

The association between de novo inflammatory bowel disease and celiac disease

DOI: 10.17235/reed.2019.5535/2018

Editorial

Online social networks and inflammatory bowel disease

DOI: 10.17235/reed.2018.5496/2018

Original

A meta-analysis of dietary carbohydrate intake and inflammatory bowel disease risk: evidence from 15 epidemiology studies

DOI: 10.17235/reed.2018.5490/2018

Letter to the Editor

Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease

DOI: 10.17235/reed.2018.5456/2018

Original

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

DOI: 10.17235/reed.2018.5368/2017

Original

Managing iron deficiency and iron deficiency anemia in inflammatory bowel disease. The results of the “Gestiona hierro-EII” survey

DOI: 10.17235/reed.2018.5354/2017

Original

Using the internet to evaluate the opinion of patients with inflammatory bowel disease with regard to the available information

DOI: 10.17235/reed.2018.5331/2017

Original

Incidence and characterization of Clostridium difficile in a secondary care hospital in Spain

DOI: 10.17235/reed.2018.5288/2017

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Original

Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index

DOI: 10.17235/reed.2017.5137/2017

Original

Fecal microbiota transplantation in refractory or recurrent Clostridium difficile infection: a real-life experience in a non-academic center

DOI: 10.17235/reed.2018.5099/2017

Editorial

The complexity of evaluating and increasing adherence in inflammatory bowel disease

DOI: 10.17235/reed.2017.5143/2017

Case Report

Serrated polyposis syndrome associated with long-standing inflammatory bowel disease

DOI: 10.17235/reed.2017.5068/2017

Case Report

Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis

DOI: 10.17235/reed.2017.5024/2017

Original

Medium to long-term efficacy and safety of oral tacrolimus in moderate to severe steroid refractory ulcerative colitis

DOI: 10.17235/reed.2017.4899/2017

Original

Prevalence, risk factors and response to treatment of extra-intestinal manifestations in patients with inflammatory bowel disease

DOI: 10.17235/reed.2017.4845/2017

Case Report

Fecal microbiota transplantation in recurrent Clostridium difficile infection in a patient with concomitant inflammatory bowel disease

DOI: 10.17235/reed.2017.4819/2016

Original

Knowledge of disease and access to a specialist reported by Spanish patients with ulcerative colitis. UC-LIFE survey

DOI: 10.17235/reed.2017.4748/2016

Original

Epidemiology of inflammatory bowel disease in Málaga: incidence rate and follow-up of a cohort diagnosed between 2007-2008

DOI: 10.17235/reed.2017.4708/2016

Letter to the Editor

Ulcerative colitis with gastric and duodenal involvement

DOI: 10.17235/reed.2017.4685/2016

Original

What is the real-life maintenance mesalazine dose in ulcerative colitis?

DOI: 10.17235/reed.2016.4620/2016

Original

The concerns of Spanish patients with inflammatory bowel disease as measured by the RFIPC questionnaire

DOI: 10.17235/reed.2017.4621/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Letter to the Editor

Invasive pulmonary aspergillosis in an immunocompromised patient with severe ulcerative colitis

DOI: 10.17235/reed.2017.4564/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Original

The use of a segmental endoscopic score may improve the prediction of clinical outcomes in acute severe ulcerative colitis

DOI: 10.17235/reed.2016.4470/2016

Original

Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease

DOI: 10.17235/reed.2016.4447/2016

Original

Risk factors for tuberculosis in inflammatory bowel disease: anti-tumor necrosis factor and hospitalization

DOI: 10.17235/reed.2016.4440/2016

Letter to the Editor

Fecal microbiota transplantation: is there a role in the eradication of carbapenem-resistant Klebsiella pneumoniae intestinal carriage?

DOI: 10.17235/reed.2017.4425/2016

Original

How is inflammatory bowel disease managed in Spanish gastroenterology departments? The results of the GESTIONA-EII survey

DOI: 10.17235/reed.2016.4410/2016

Letter to the Editor

Pharmaceutical costs for inflammatory bowel disease units — An issue for department heads? The GESTIONAEII survey

DOI: 10.17235/reed.2016.4192/2016

Original

Meta-analysis of the association between appendiceal orifice inflammation and appendectomy and ulcerative colitis

DOI: 10.17235/reed.2016.4176/2015

Digestive Diseases Image

All that glitters is not gold. A different cause for an "ulcerative colitis"

Letter to the Editor

Ulcerative colitis in a patient with common variable immunodeficiency: does the treatment differ from the routine?

DOI: 10.17235/reed.2016.4115/2015

Original

Initial experience with golimumab in clinical practice for ulcerative colitis

DOI: 10.17235/reed.2016.4068/2015

Original

Endoluminal calprotectin measurement in assessment of pouchitis and a new index of disease activity: a pilot study

DOI: 10.17235/reed.2016.4066/2015

Original

Characteristics of Clostridium difficile infection in patients with discordant diagnostic test results

DOI: 10.17235/reed.2016.4052/2015

Case Report

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Original

Idiopathic portal hypertension regarding thiopurine treatment in patients with inflammatory bowel disease

DOI: 10.17235/reed.2015.3954/2015

Letter to the Editor

Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients

DOI: 10.17235/reed.2015.3978/2015

Editorial

INTENSIFICATION OF MAINTENANCE THERAPY WITH INFLIXIMAB IN ULCERATIVE COLITIS

DOI: 10.17235/reed.2015.3907/2015

Digestive Diseases Image

Nodular colitis: endoscopic image an unusual finding

Case Report

Immmunodeficiencies and autoimmune diseases: common variable immunodeficiency and Crohn-like

DOI: 10.17235/reed.2015.3872/2015

Original

FREQUENCY, PREDICTORS, AND CONSEQUENCES OF MAINTENANCE INFLIXIMAB THERAPY INTENSIFICATION IN ULCERATIVE COLITIS

DOI: 10.17235/reed.2015.3804/2015

Original

Impact of the age of diagnosis on the natural history of ulcerative colitis

DOI: 10.17235/reed.2015.3736/2015

Citation tools
Izquierdo Romero M, Varela Trastoy P, Mancebo Mata A. Fecal transplantation as a treatment for Clostridium difficile infection in patients with ulcerative colitis. 4941/2017


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1149 visits.
This article has been downloaded 280 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 08/03/2017

Accepted: 22/03/2017

Online First: 27/07/2017

Published: 31/08/2017

Article Online First time: 141 days

Article editing time: 176 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
REED awards
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
REED awards
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
Home
Articles
Current issues
Previous issues
Most read articles
Clinical guidelines
Reviews
Topic collection
Submit a manuscript
Submit a manuscript
Information for authors
Language editing services
Editorial time – Publication time
REED awards
ORCID guide
PubMed guide
Journal info
About the journal
Editorial board
For reviewers
For advertisers
REED centenary
Open access
Articles in press
Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology